- Home
- RLYB vs CNTB Comparison
RLYB vs CNTB Comparison
Compare RLYB & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | CNTB |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 157.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLYB | CNTB |
|---|---|---|
| Price | $0.73 | $2.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 177.2K | ★ 659.9K |
| Earning Date | 11-06-2025 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $674,000.00 | ★ $762,000.00 |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | $38,289.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.71 | N/A |
| 52 Week Low | $0.22 | $0.51 |
| 52 Week High | $1.20 | $3.28 |
Technical Indicators
Market Signals| Indicator | RLYB | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 46.85 |
| Support Level | $0.72 | $2.27 |
| Resistance Level | $0.80 | $2.56 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 84.86 | 2.78 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.